Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...
Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be ...
Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...
Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...
I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...
Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning ladies and gentlemen and welcome to PDS Biotech’s Third Quarter 2024 Results and Clinical Strategy Update Conference Call. All ...
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...
PDS Biotechnology shares declined after it issued an update about a cancer study with a combination of Versamune HPV and pembrolizumab and reported quarterly results. The stock was down 18%, to $2.25, ...
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
Media ReleaseEfti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients ...